Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isotretinoin plus interferon alfa-2a versus interferon alfa-2a alone as adjuvant therapy for high-risk primary cutaneous melanoma
2005-001679-36Phase 3Completed
- Sponsor
- Kožní ordinace
- Start
- Jun 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) comparing Roaccutane + Roferon-A with Roferon-A alone (2 arms). Primary endpoints: Proportion of patients with distant relapse within 5 years and Time from surgery to distant relapse. Started Jun 2005; status: completed.
02
Drugs
isotretinoininterferon alfa
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2005-001679-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001679-36.